• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

    6/25/26 9:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNY alert in real time by email

    Expanded agreement extends Marmot across key enterprise functions, advancing a new operating model for AI-powered decision-making in Life Sciences

    Komodo also unveils new Marmot capabilities to move organizations beyond AI experimentation and into enterprise-wide intelligence

    Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (NASDAQ:ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo’s analytics AI platform, across key enterprise functions at Alnylam.

    Built on the Healthcare Map®, the industry’s most comprehensive view of more than 330 million de-identified patient journeys, Marmot helps organizations move beyond fragmented analytics and static reporting toward real-time, transparent, and reproducible healthcare intelligence. Launched in August 2025, Alnylam was an early adopter of the platform, with the collaboration initially focused on building custom AI agents for Alnylam’s commercial business function.

    The expanded partnership will enable Alnylam to deploy Marmot across its customer-facing organization and leverage its capabilities more broadly across the enterprise, creating a unified foundation for data-driven decision-making at scale.

    "Alnylam’s ability to create meaningful impact is built on breakthrough science, strong execution, and an unwavering commitment to patients," said Tolga Tanguler, Chief Commercial Officer at Alnylam. "This new capability strengthens our ability to connect insight into action, helping us scale more effectively, accelerate decision-making, and continue delivering sustainable growth while maintaining our focus on patients."

    Since initially deploying Marmot, Alnylam and Komodo have built and deployed custom AI agents across critical workflows. Alnylam has integrated a wide range of enterprise datasets into the platform, transforming how teams access and act on insights by eliminating reliance on fragmented dashboards, reducing reporting cycles from months to hours, and enabling teams to generate insights that were previously out of reach. Marmot will continue to support Alnylam as the company works toward a range of operational and patient impact objectives.

    Advancing the Next Generation of Enterprise Healthcare AI

    The expanded partnership reflects a broader shift occurring across healthcare and Life Sciences as organizations move beyond AI experimentation and begin adopting new operating models built around real-time intelligence. As the limitations of disconnected dashboards, static reporting, and siloed analytics become increasingly apparent, the focus is turning toward enterprise-wide systems that can continuously generate, distribute, and operationalize trusted, verifiable insights across teams.

    "We’re moving from a world where every team operates from its own reports and analyses to one where an entire enterprise sees the same reality in real time and can act on it," said Arif Nathoo, MD, CEO and Co-Founder of Komodo Health. "Marmot is not only a productivity improvement; it’s a new operating model. Alnylam is demonstrating what becomes possible when AI evolves into an intelligence layer that powers how an organization runs."

    New Marmot Capabilities Support Enterprise-Wide Adoption

    To support this next phase of enterprise AI adoption, Komodo also released several new Marmot capabilities designed to make healthcare intelligence accessible to every user, from business leaders and consultants to analysts and data scientists. These latest capabilities deliver unprecedented visibility, knowledge, and control over healthcare data, ensuring every analysis is reproducible, verifiable, and executed with unmatched speed and confidence.

    "The organizations seeing the greatest value from AI aren’t simply generating insights faster; they’re embedding trusted intelligence directly into the workflows that drive critical decisions," said Amit Sangani, Chief Technology Officer at Komodo. "These new capabilities are designed to help organizations move beyond experimentation and build AI into the core processes that drive the enterprise, without sacrificing the scientific rigor healthcare demands."

    To learn more, register for today’s live launch event at 1 PM ET/ 10 AM PT here or visit our Product Updates page.

    About Komodo Health

    Komodo Health® is building the trusted AI-powered intelligence layer for healthcare and Life Sciences. Powered by the Healthcare Map®, the industry’s most comprehensive view of more than 330 million de-identified patient journeys, Komodo’s healthcare-native AI analytics platform, Marmot™, equips organizations with the intelligence needed to answer critical healthcare questions across clinical development, market access, commercialization, and real-world evidence. Designed for transparency, auditability, and reproducibility, Marmot enables teams to move from question to decision with greater speed and confidence. For more information, visit komodohealth.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260625007024/en/

    Media Contact

    Tate LaCasse

    PR Manager

    media@komodohealth.com

    Get the next $ALNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNY

    DatePrice TargetRatingAnalyst
    5/19/2026$380.00Buy
    Citigroup
    3/16/2026$330.00Buy → Hold
    Jefferies
    1/28/2026$527.00Overweight
    Barclays
    1/7/2026$500.00Outperform
    Oppenheimer
    8/4/2025Underperform → Peer Perform
    Wolfe Research
    8/4/2025$490.00Perform → Outperform
    Oppenheimer
    7/30/2025$370.00Outperform
    Raymond James
    7/21/2025$385.00Buy
    Truist
    More analyst ratings

    $ALNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

    4/30/24 1:44:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling

    9/20/23 2:36:38 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling

    2/17/23 12:30:09 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pyott David E I sold $1,145,853 worth of shares (3,830 units at $299.18) as part of a pre-agreed trading plan and converted options into 3,830 shares (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    6/3/26 4:25:20 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Cravatt Benjamin

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    6/3/26 4:23:40 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Cravatt Benjamin

    3 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    6/3/26 4:21:30 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    SEC Filings

    View All

    SEC Form 144 filed by Alnylam Pharmaceuticals Inc.

    144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    6/1/26 4:25:14 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    5/27/26 4:30:22 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Alnylam Pharmaceuticals Inc.

    SCHEDULE 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    5/6/26 11:00:55 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Reitan Colleen F bought $10,363 worth of shares (36 units at $287.85), sold $8,383 worth of shares (36 units at $232.86) and was granted 775 shares (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    5/12/25 4:05:00 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

    Expanded agreement extends Marmot across key enterprise functions, advancing a new operating model for AI-powered decision-making in Life Sciences Komodo also unveils new Marmot capabilities to move organizations beyond AI experimentation and into enterprise-wide intelligence Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (NASDAQ:ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo’s analytics AI platform, across key enterprise functions at Alnylam. Built on the Healthcare Map®, the industry’s most comprehensive view of more than 330 million de-identified patient journeys

    6/25/26 9:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam to Host Tenth "RNAi Roundtable" Webcast Series

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of "RNAi Roundtable" webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company's pipeline programs, as well as medical thought leaders who will provide their perspectives on unmet clinical needs. Each event will be webcast live on the Investors section of the Company's website at investors.alnylam.com/events, and a replay will be posted on the Alnylam website approximately three hours after each event. The 2026 RNAi Roundtable schedule is as f

    6/12/26 9:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

    − Collaboration is valued at up to $2B with upfront consideration of $30M − − Alliance pairs Alnylam's RNAi platform and 20+ years of proprietary data with Inceptive's foundation models and AI expertise to catalyze progress beyond rational drug design – − Partnership designed to accelerate timelines and unlock innovative oligonucleotide designs − Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration agreement to increase the pace of therapeutic innovation. The collaboration is valued at up to $2B with upfront consideration of $30M, including cas

    6/3/26 4:45:00 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Alnylam Pharma with a new price target

    Citigroup initiated coverage of Alnylam Pharma with a rating of Buy and set a new price target of $380.00

    5/19/26 8:29:23 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharma downgraded by Jefferies with a new price target

    Jefferies downgraded Alnylam Pharma from Buy to Hold and set a new price target of $330.00

    3/16/26 8:35:18 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Alnylam Pharma with a new price target

    Barclays resumed coverage of Alnylam Pharma with a rating of Overweight and set a new price target of $527.00

    1/28/26 7:15:18 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Leadership Updates

    Live Leadership Updates

    View All

    Alnylam Pharmaceuticals Announces Changes to Board of Directors

    – Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new independent director. Mike Bonney and Carolyn Bertozzi, Ph.D., who have served in key roles on Alnylam's Board, stepped down effective December 2, 2025. Mr. Bonney joined our Board in 2014 and served as Board Chair from December 2015 to August 2021 and as Executive Chair from August 2021 to January 2023. He helped to guide the company through major milestones and significant growt

    12/3/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

    Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

    9/18/25 9:15:00 AM ET
    $ALNY
    $ILMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

    3/5/25 7:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Financials

    Live finance-specific insights

    View All

    $ALNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

    − Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million (121% Growth Compared with Q1 2025), Driven Primarily by Total TTR Revenues of $910 Million (153% Growth Compared with Q1 2025) – − Reiterates 2026 Financial Guidance, Including Combined Net Product Revenues of $4,900 Million to $5,300 Million, and Total TTR Net Product Revenues of $4,400 to $4,700 Million – − New Data Presented at ACC.26 Further Support Use of Vutrisiran as First-Line Treatment for ATTR-CM – − Established Collaborations with Viz.ai and AHA Focused on Earlier Diagnosis, Coordinated Care and Long-Term Patient Impact in ATTR-CM – − Deep Pipeline Progressing Toward Multiple Clinical Readouts Du

    4/30/26 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday, April 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2026 results as well as expectations for the future via conference call on Thursday, April 30, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceut

    4/16/26 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

    − Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024 – − Attained GAAP and non-GAAP Profitability for Full Year 2025, with Sustainable Growth in Operating Income Expected – − Launched "Alnylam 2030" Strategy Focused on Scaling Alnylam through Durable ATTR Leadership, Long-Term Sustainable Innovation, and Exceptional Financial Results – − Announced 2026 Pipeline Goals, Including 4 Clinical Readouts, 3 Ongoing Pivotal Studies, 3 Phase 2 Study Initiations, and 3+ New IND Filings – − Reiterates Net Product Sales Guidance and Provides Additional 2026 Fin

    2/12/26 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/12/24 9:50:12 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/8/24 10:34:33 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    8/12/24 9:40:06 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care